• Introduction to Myeloma
  • News
  • Multiple Myeloma Q&A
  • Testimonials
  • Press Releases
  • Resources
  • Biography
  • Resume
  • Contact
Subscribe: Posts | Comments

James R. Berenson, MD, Inc.

Berenson Oncology
  • Introduction to Myeloma
  • News
  • Multiple Myeloma Q&A
  • Testimonials
  • Press Releases
  • Resources
  • Biography
  • Resume
  • Contact
RSS

Archive | Movie Premier RSS feed for this section

Love Is All You Need – Movie Premiere Benefiting the Institute for Myeloma & Bone Cancer Research

March 28, 2013

0 Comments

LoveIsAllYouNeed3… Article

Continue reading...

James R. Berenson, MD

James R. Berenson, MD

  • President & CEO, Institute for Myeloma & Bone Cancer Research (IMBCR)
  • President & Medical Director. Berenson Cancer Center (Berensoncancercenter)
  • Founder & President, ONCOtherapeutics
  • Founder & Principal, ONCOtracker
Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:
  • Monoclonal gammopathy of undetermined significance (MGUS)
  • Asymptomatic (smoldering/indolent) myeloma
  • solitary plasmacytoma of the bone
  • Extramedullary plasmacytoma
  • Light chain myeloma
  • Non-secretory myeloma
  • Osteosclerotic myeloma (POEMS syndrome)
  • Waldenstrom macroglobulinemia
  • Light chain amyloidosis
  • Plasma cell leukemia
  • Latest
  • Popular
  • Comments
  • Tags
  • James R. Berenson Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study February 8, 2022
  • Emory Universitys Big Discovery IMBCR & Emory University’s Big Discovery!!! February 7, 2022
  • Berenson Cancer Center James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center February 6, 2022
  • What Is Multiple Myeloma? January 10, 2019
  • Video Updates June 26, 2018
  • Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients February 16, 2011
  • The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo March 19, 2011
  • Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting November 23, 2011
  • Understanding Myeloma News About Secondary Cancers and Clotting May 28, 2012
  • Dedication of “Determination” Dedication of “Determination” June 1, 2012
accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma ASCO B-cell maturation antigen BCMA Biomarker Bortezomib bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory Carfilzomib Dedication HevyLite; immunoglobulins; multiple myeloma; outcomes IMBCR Kyprolis lenalidomide monoclonal antibodies more is not better Multiple Myeloma myeloma Overall survival Pomalyst proteasome inhibitors Revlimid Secondary Cancers TRAF6 transplant update

Links

  • American Cancer Society
  • American Society of Clinical Oncology
  • American Society of Hematology
  • Cancer Support Community
  • Institute for Myeloma & Bone Cancer Research
  • Leukemia & Lymphoma Society®
  • National Institutes of Health
  • Oncotherapeutics

Subscribe

Subscribe to our e-mail newsletter to receive updates.

Contact Us

9201 W. Sunset Blvd. Ste. 310
West Hollywood, CA 90069
Tel  (310) 623-1222
Fax (310) 623-1122
info@berensoncancercenter.com

Sunset Medical Plaza
© 2012-2018 James R. Berenson, MD, Inc. All rights reserved.
Privacy Policy | Sitemap
Scroll Up